Hum. Reprod. Advance Access published online on July 10, 2006
Human Reproduction, doi:10.1093/humrep/del267
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Obstetrics & Gynecology, University ‘Magna Graecia’ of Catanzaro, Catanzaro, Italy
* To whom correspondence should be addressed. BACKGROUND: Previous data on the efficacy of clomiphene citrate, the most commonly used drug for treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS), have shown a discrepancy between ovulation and pregnancy rates. In the present subanalysis (of a larger previously published randomized controlled trial), the effect of clomiphene citrate on several ultrasonographic markers of uterine receptivity in PCOS patients who ovulated under treatment was studied. METHODS: Thirty-three PCOS women who ovulated under 150 mg daily clomiphene citrate and 33 healthy controls were studied. Uterine, subendometrial and endometrial blood flows, endometrial thickness and pattern were assessed using serial ultrasonographic assessments. The data were analysed before and after grouping the clomiphene citrate-stimulated ovulatory cycles for reproductive outcome [unfavourable (ovulation alone or early pregnancy loss) or favourable outcome (clinical pregnancy and/or live birth)]. RESULTS: Both before and during treatment, uterine vascularity assessed at all sites was significantly lower in the PCOS group than in controls. Endometrial thickness and pattern were impaired in the PCOS group under clomiphene citrate treatment. A significant difference in all ultrasonographic parameters was observed between cycles ending in unfavourable versus those ended in favourable outcome. CONCLUSIONS: Clomiphene citrate administration alters several surrogate ultrasonographic parameters of uterine receptivity, and this effect could be crucial for its efficacy.
Received April 14, 2006
Revised May 30, 2006
Accepted June 12, 2006
Article
Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study
Stefano Palomba 1 *,
Tiziana Russo 1,
Francesco Orio Jr 2,
Angela Falbo 1,
Francesco Manguso 3,
Annalidia Sammartino 4,
Achille Tolino 4,
Annamaria Colao 5,
Enrico Carmina 6,
and
Fulvio Zullo 1
2 Department of Molecular & Clinical Endocrinology and Oncology, University ‘Federico II’ of Naples, Naples
3 Department of Clinical and Experimental Medicine, University ‘Federico II’ of Naples, Naples
4 Department of Obstetrics & Gynecology, University ‘Federico II’ of Naples, Naples
5 Department of Molecular & Clinical Endocrinology and Oncology, , University ‘Federico II’ of Naples, Naples
6 Department of Endocrinology, University of Palermo, Palermo, Italy
Stefano Palomba, E-mail: stefanopalomba{at}tin.it
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, F. Orio Jr., A. Falbo, T. Russo, A. Tolino, and F. Zullo Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3498 - 3503. [Abstract] [Full Text] [PDF]
|
|